Cancer Genetics, Inc. (CGI), an emerging leader in cancer diagnostics, and vivoPharm Pty. Ltd. yesterday announced they have entered into a definitive agreement for Cancer Genetics to acquire vivoPharm for approximately $12 million USD.
This transaction will significantly strengthen CGI’s position as a premier leader for oncology discovery, in vivo and in vitro drug development and early phase clinical trial testing for biotechnology and pharmaceutical companies. With over a decade of experience in delivering a wide range of discovery and preclinical services to support drug development, target validation and biomarker analysis, vivoPharm has supported over 200 Investigational New Drug (IND) submissions for innovative therapies, with a significant focus on immuno-oncology.
vivoPharm has developed industry recognized capabilities in early phase development and discovery, especially in immuno-oncology models, tumor micro-environment studies, specialized pharmacology services, and PDx (patient derived xenograft) model studies that support basic discovery, preclinical and phase 1 clinical trials.
As a market-leading contract research organization (CRO), vivoPharm services approximately forty clients, the majority of which are located outside the U.S., with its diverse client base, ranging from virtual biotech companies to large top 10 pharmaceutical companies.